Rapport Therapeutics (RAPP) Interest Expenses (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Interest Expenses of $123.8 million for Q1 2026, down 98.98% year-over-year from $12.2 billion in Q1 2025, and up 8.78% quarter-over-quarter from $113.8 million in Q4 2025.
Rapport Therapeutics (RAPP) Interest Expenses (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Interest Expenses for 4 consecutive years, with $123.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 98.98% year-over-year to $123.8 million; the TTM figure through Mar 2026 stood at $123.8 million (down 98.98% YoY), while the FY2025 annual figure was $113.8 million, up 231.66% from the prior year.
- Interest Expenses climbed to $123.8 million in Q1 2026 per RAPP's latest filing, from $113.8 million in the prior quarter.
- Across five years, Interest Expenses topped out at $12.2 billion in Q1 2025 and bottomed at $9.6 million in Q2 2023.
- Historically, Interest Expenses has averaged $1.3 billion across 4 years, with a median of $50.5 million in 2024.
- Annual changes were most pronounced in 2024 — Interest Expenses surged 483.47% — and 2026, when it plunged 98.98%.
- Rapport Therapeutics' Interest Expenses stood at $13.1 million in 2023, then surged by 161.12% to $34.3 million in 2024, then soared by 231.66% to $113.8 million in 2025, then increased by 8.78% to $123.8 million in 2026.
- Business Quant data shows RAPP's Interest Expenses at $123.8 million in Q1 2026, $113.8 million in Q4 2025, and $112.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 202.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 202.71 Mn |
| Jun 30, 2026 | 202.71 Mn |
| Mar 31, 2026 | 123.84 Mn |
| Mar 31, 2026 | 123.84 Mn |
| Dec 31, 2025 | 113.84 Mn |
| Dec 31, 2025 | 113.84 Mn |
| Sep 30, 2025 | 112.36 Mn |
| Sep 30, 2025 | 112.36 Mn |
| Jun 30, 2025 | 16.80 Mn |
| Jun 30, 2025 | 16.80 Mn |
| Mar 31, 2025 | 12.19 Bn |
| Mar 31, 2025 | 12.19 Bn |
| Dec 31, 2024 | 34.32 Mn |
| Dec 31, 2024 | 34.32 Mn |
| Sep 30, 2024 | 44.99 Mn |
| Sep 30, 2024 | 44.99 Mn |
| Jun 30, 2024 | 56.01 Mn |
| Jun 30, 2024 | 56.01 Mn |
| Dec 31, 2023 | 13.15 Mn |
| Dec 31, 2023 | 13.15 Mn |